For personal use only Disclaimer and important information Disclaimer and important notice This presentation has been prepared by McMillan Shakespeare Limited ABN 74 107 233 983 ("MMS"). It contains summary information about MMS and its subsidiaries and their activities current as at the date of this presentation. The presentation contains selected information and does not purport to be all inclusive or to contain information that may be relevant to a prospective investor. No reliance may be placed on MMS f ...

FITZROY ISLAND | CAIRNS | AUSTRALIA DISCLAIMER Summary information FY25 RESULTS PRESENTATION For personal use only EXPERIENCE CO LIMITED | FY25 RESULTS | AUGUST 2025 This presentation has been prepared by Experience Co Limited (ASX: EXP) contains summary information about EXP and its related bodies corporate and their activities. The information in this presentation is of a general background nature and does not purport to be complete or comprise all the information that an investor would require when makin ...

Financial Performance - MOVE Logistics Group's FY25 revenue was NZD 286.3 million [58] - Normalised Earnings Before Tax (NEBT) improved by 61.1% year-over-year [17, 28], representing a NZD 15.7 million increase [59] - Gross Margin increased by 13.4% to NZD 83.5 million [18, 25], with Gross Margin percentage up by 4.1 percentage points to 29.2% [18, 26] - Net Loss After Tax (NLAT) improved by NZD 32.5 million [59] to NZD -15.6 million [58] Transformation Programme & Cost Reduction - The "Accelerate Transformation Programme" delivered approximately NZD 27 million in cost reductions in FY25 [22, 60] - People costs decreased by approximately NZD 15 million [62] - Transport costs, as a percentage of Freight revenue, decreased by 5.1 percentage points [62] Business Segment Performance - Freight and Fuel segment revenue was NZD 188.8 million [35, 36], with a 90% improvement in NEBT loss [21, 39] - Specialist segment revenue increased to NZD 18.2 million [47, 48], with Normalised EBT at NZD 2.3 million [47, 49] - International segment revenue increased to NZD 25.7 million [53, 54], with Normalised EBT at NZD 0.3 million [53, 55] Future Outlook - The company is targeting a return to positive normalised EBT in FY26 [80]

Financial Performance - Revenue from cell therapy products reached US$172 million, a 191% increase compared to the previous year[30] - Ryoncil's successful launch contributed US$132 million in gross sales and US$113 million in reported net sales after a 146% gross to net adjustment[30] - Net operating cash spend was US$50 million, a 3% increase on prior year[30] - Cash on hand at June 30, 2025, was US$162 million (A$247 million)[30] Ryoncil (remestemcel-L) - Ryoncil became the first FDA-approved MSC product in the US in December 2024 and commercially available on March 28, 2025[24] - The company onboarded 32 US transplant centers, aiming for the top 45 centers (80% of pediatric bone marrow transplants) by the end of the quarter[24] - Ryoncil demonstrated a 70% overall response rate at Day 28 in a Phase 3 trial for SR-aGvHD[41,43] - In children from GVHD001 trial, 49% survival at Year 4, with only 14% (N=7) died due to aGvHD through 4 years[44] Market Opportunities - Steroid-refractory acute GvHD for children & adults represents a ~US$1 billion market[21] - Biologic-refractory inflammatory bowel disease represents a >US$5 billion market[21] - Heart failure with reduced ejection fraction (HFrEF) represents a >US$10 billion market[21] - Chronic low back pain (CLBP) represents a >US$10 billion market[21]

Financial Performance - Operating revenue decreased by 3.4% from $24.75 million in FY24 to $23.90 million in FY25[13, 15] - MetroMap subscription revenue increased by 11.5% to $9.57 million in FY25[12, 14, 18, 65, 68] - Subscription revenue now contributes 40% of total revenue[12, 65] - MetroMap Annual Contract Value (ACV) grew by 12.8% to $10.56 million[13, 14, 16, 18, 65, 69] - 3D revenue increased significantly by 78.4% to $1.53 million[14, 29, 65] - LiDAR revenue decreased by 22.8% to $10.92 million[25, 65] - EBITDA increased by 19.8% from $2.89 million in FY24 to $3.46 million in FY25[13, 68, 70] Strategic Focus - The company is focused on scaling revenue and driving cash generation[66] - Key focus areas for FY26 include driving ACV and off-the-shelf sales for MetroMap, building the MetroMap Program Partner model, and product enhancements[57, 61] - The company aims to build and accelerate the opportunity pipeline for LiDAR and explore new market opportunities in renewables and carbon farming[58, 61] - For Global 3D, the company plans to pursue Australian project opportunities and continue to build awareness and capability in international markets[59, 61]

Financial Performance Summary - Enero Group's net revenue from continuing operations decreased by 3% from A$143.5 million in FY24 to A$138.7 million in FY25[39] - EBITDA from continuing operations increased by 2% from A$13.9 million in FY24 to A$14.1 million in FY25[39] - EBITDA margin from continuing operations increased by 0.5 percentage points, from 9.7% in FY24 to 10.2% in FY25[39] - Including discontinuing operations (OBMedia), net revenue decreased by 11% from A$189.7 million in FY24 to A$168.3 million in FY25[39] - Including discontinuing operations, EBITDA decreased by 30% from A$37.4 million in FY24 to A$26.2 million in FY25[39] - Including discontinuing operations, EBITDA margin decreased by 4.1 percentage points, from 19.7% in FY24 to 15.5% in FY25[39] Segment Performance - The Technology, Healthcare & Consumer (THC) Practice saw a 3% decrease in revenue, from A$143.5 million to A$138.7 million, but EBITDA increased slightly by 0.2% from A$22.8 million to A$22.9 million[40] - Hotwire Global's revenue decreased by 4% from A$81.7 million to A$78.6 million, but EBITDA increased by 15% from A$9.6 million to A$11.1 million[12] - BMF's revenue decreased by 2% from A$35.0 million to A$34.4 million, and EBITDA decreased by 14% from A$8.0 million to A$6.9 million[12] Half-on-Half Performance - In the THC Practice, H2 revenue increased by 2% compared to H1 (A$70.1 million vs A$68.7 million)[8] - The THC Practice's EBITDA margin improved by 1.7 percentage points from H1 to H2 (9.3% vs 11.0%)[8] - Corporate costs reduced 24% in FY25 H2 on prior half and in FY25 H2 represents 4.7% of revenue (excluding share-based payments)[9]

Financial Performance - Sales revenue increased by 4% to $249.4 million[16, 17, 18] - Underlying EBITDA decreased by 2% to $33.2 million[16, 17, 18] - Underlying EBIT decreased by 8% to $20.6 million[16, 17, 18] - Statutory NPAT decreased significantly by 31% to $9.6 million[16, 17, 18] - Underlying EPS decreased by 12% to 35.2 cents[17, 18] - Total dividend remained consistent at 15 cents per share fully franked[16, 18] Regional Performance - Australia and New Zealand EBIT decreased by 15% to $13 million[17] - North America and Europe EBIT increased by 25% to $4.3 million[17] - Asia EBIT decreased by 9% to $3.3 million[17] Balance Sheet - Net debt decreased by $8 million, improving the gearing ratio from 25% to 17%[48] - Cash and cash equivalents increased to $24.5 million from $16.8 million[58, 60]

Financial Performance - Total revenue grew by 20% year-over-year to $415 million[116, 118] - Sales-led subscription revenue increased by 22% year-over-year, reaching $339 million[116, 118] - Elastic Cloud revenue grew by 24% year-over-year, totaling $196 million[116, 118] - Sales-led subscription revenue accounted for 82% of total revenue[118] - Non-GAAP operating margin was 16%[116, 130] - Adjusted free cash flow was $116 million, representing 28% of total revenue[131, 141] Customer Base - The company has 1,550 customers with ACV (Annual Contract Value) greater than $100K[117] - The net expansion rate is 112%[128] Future Outlook - The company projects total revenue between $415 million and $417 million for Q2 FY26, representing 14% year-over-year growth[132] - The company projects total revenue between $1.679 billion and $1.689 billion for FY26, representing 14% year-over-year growth[132] Platform and Technology - 72% of organizations have adopted AI in one or more business functions[18] - Elastic's Search AI Lake provides response times in milliseconds[34] - Elastic ingests 400 terabytes of telemetry data per day with Elastic Observability[54]

Financial Performance - Q2 FY26 - Billings reached $1,678 million, a 36% year-over-year increase[5] - Revenue totaled $1,763 million, up 17% year-over-year[5] - GAAP operating margin was 25%, a 2 percentage point increase[5] - Non-GAAP operating margin was 39%, a 1 percentage point increase[5] - Free cash flow was $451 million, a 122% increase[5] Revenue Breakdown - Q2 FY26 - Design revenue was $1,472 million, up 17% year-over-year (18% in constant currency)[7] - Make revenue was $194 million, up 20% year-over-year (20% in constant currency)[7] - Americas revenue was $786 million, up 19% year-over-year (19% in constant currency)[7] - AECO revenue was $878 million, up 23% year-over-year (24% in constant currency)[7] FY26 Outlook - Billings are projected to be between $7,355 million and $7,445 million[9] - Revenue is projected to be between $7,025 million and $7,075 million[9] - Free cash flow is projected to be between $2,200 million and $2,275 million[9]

Q2 Fiscal 2025 SECOND QUARTER RESULTS August 28, 2025 Forward Looking Statements / Non-GAAP Financial Measures FORWARD LOOKING STATEMENTS These materials and related earnings press release and conference call contain forward-looking statements within the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements other than those that are purely historical are forward-looking statements. Forward- looking statements include statements identified as such in our August 28, ...